Abpro bags $60M in near-term R&D cash in tie-up with China's NJCTTQ, with eyes on bispecific T cell engagers
As Abpro marches toward human testing for its first immuno-oncology drug, the Woburn, MA-based synthetic biology player has scored $60 million in a sizable development deal with a Chinese partner.
The partnership with NJCTTQ — a storied pharma with a fleet of R&D and sales staffers in China — marks Abpro’s first high profile pact since tying up with AstraZeneca’s MedImmune three years ago. And the two deals share the same focus: bispecific antibodies.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
